Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart stent under Real-World watch: will it hold up?

NCT ID NCT04899141

Disease control Sponsor: Fundación EPIC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 400 people with coronary artery disease who received the ihtDEStiny drug-eluting stent during a routine procedure to open blocked heart arteries. Researchers are monitoring how well the stent works over time, including rates of heart attacks, repeat procedures, and deaths. The goal is to see if this stent performs safely in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ihtDEStiny sirolimus-eluting coronary stent
What this could lead to
If successful, this registry could confirm that the ihtDEStiny stent is safe and effective for routine use in opening blocked heart arteries.
What could go wrong
This is an observational registry, not a randomized trial, so it cannot prove the stent is better than other stents. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

400 people

The number who actually took part.

Started

Oct 2021

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with all inclusion criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years old * PCI and stent implantation indication according to ESC Myocardial Revascularization Guidelines * 1 or more stenosis at native coronary anatomy, in a 2-4mm vessel size, where 1 or more ihtDEStiny® drug eluting stent were implanted (or attempted to be implanted). * Informed consent signed after PCI Exclusion Criteria: * Patient refusal to participate in the study * Pregnancy * Other DES implantation during index PCI, or 30 days before of after index PCI * PCI at surgical grafts * PCI for in-stent restenosis * Killip class 3-4 Acute Coronary Syndromes (ACS) * High bleeding risk with dual antiplatelet intolerance for at least 3 months (or 6 months for ACS PCI) * Allergy or hypersensitivity to sirolimus * Patients requiring surgery (cardiac or non-cardiac) in the next 3 months after index PCI * Patients with life expectancy \<2 years * Patients included in other trials or clinical studies

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary artery disease Ischemic heart disease

Contacts and locations

Locations

  • Centro Hospitalar Universitario Do Algarbe

    Faro, 8000-386, Portugal

  • Hospital Clinico Universitario Lozano Blesa

    Zaragoza, 50009, Spain

  • Hospital Clinico Universitario Santiago de Compostela

    Santiago de Compostela, 15706, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital General Universitario de Ciudad Real

    Ciudad Real, 13005, Spain

  • Hospital General Universitario de Elche

    Elche, 03203, Spain

  • Hospital San Pedro de Alcantara

    Cáceres, 10003, Spain

  • Hospital Universitari Arnau de Vilanova de Lleida

    Lleida, 25198, Spain

  • Hospital Universitari Vall D'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, 08907, Spain

  • Hospital Universitario Donostia

    Donostia / San Sebastian, 20014, Spain

  • Hospital Universitario Juan Ramon Jimenez

    Huelva, 21005, Spain

  • Hospital Universitario Lucus Agusti

    Lugo, 27003, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario Regional de Malaga Carlos Haya

    Málaga, Malaga, 29010, Spain

  • Hospital Universitario Virgen Arrixaca

    Murcia, 30120, Spain

  • Hospital Universitario Virgen de La Victoria

    Málaga, 29010, Spain

  • Hospital Universitario de Araba

    Vitoria-Gasteiz, 01009, Spain

  • Hospital Universitario de Cruces

    Barakaldo, 48903, Spain

  • Hospital de Galdakao

    Galdakao, 48960, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.